SC 13G/A | 2023-02-14 | Beryl Capital Management LLC | LogicBio Therapeutics, Inc. | 0 | 0.0% | EDGAR |
SC 13D/A | 2023-02-10 | Arix Bioscience plc | LogicBio Therapeutics, Inc. | 0 | 0.0% | EDGAR |
SC 13G/A | 2022-10-20 | Andera Partners | LogicBio Therapeutics, Inc. | 2,287,413 | 7.2% | EDGAR |
SC 13G | 2022-10-13 | Beryl Capital Management LLC | LogicBio Therapeutics, Inc. | 3,259,821 | 9.9% | EDGAR |
SC 13D/A | 2022-05-04 | Arix Bioscience plc | LogicBio Therapeutics, Inc. | 1,834,531 | 5.6% | EDGAR |
SC 13D/A | 2022-02-15 | Arix Bioscience plc | LogicBio Therapeutics, Inc. | 2,183,211 | 6.6% | EDGAR |
SC 13G/A | 2022-02-04 | FRANKLIN RESOURCES INC | LogicBio Therapeutics, Inc. | 1,598,695 | 4.9% | EDGAR |
SC 13D/A | 2021-10-26 | Arix Bioscience plc | LogicBio Therapeutics, Inc. | 2,983,529 | 9.2% | EDGAR |
SC 13G/A | 2021-02-16 | Nussbaum Ran | LogicBio Therapeutics, Inc. | 1,499,053 | 4.7% | EDGAR |
SC 13G/A | 2021-02-12 | Andera Partners | LogicBio Therapeutics, Inc. | 1,787,913 | 5.6% | EDGAR |
SC 13G/A | 2021-02-11 | ADAGE CAPITAL PARTNERS GP, L.L.C. | LogicBio Therapeutics, Inc. | 0 | 0.0% | EDGAR |
SC 13G/A | 2021-02-11 | Nussbaum Ran | LogicBio Therapeutics, Inc. | 1,629,053 | 5.1% | EDGAR |
SC 13G | 2021-02-01 | FRANKLIN RESOURCES INC | LogicBio Therapeutics, Inc. | 1,598,644 | 5.0% | EDGAR |
SC 13D/A | 2020-10-06 | ORBIMED ADVISORS LLC | LogicBio Therapeutics, Inc. | 3,821,293 | 12.0% | EDGAR |
SC 13D/A | 2020-09-29 | Arix Bioscience plc | LogicBio Therapeutics, Inc. | 2,381,436 | 10.1% | EDGAR |
SC 13G/A | 2020-02-21 | Barzel Adi | LogicBio Therapeutics, Inc. | 1,033,462 | 45.0% | EDGAR |
SC 13G | 2020-02-14 | Nussbaum Ran | LogicBio Therapeutics, Inc. | 1,787,413 | 7.7% | EDGAR |
SC 13G/A | 2020-02-12 | ADAGE CAPITAL PARTNERS GP, L.L.C. | LogicBio Therapeutics, Inc. | 1,246,554 | 5.4% | EDGAR |
SC 13G | 2019-05-17 | ADAGE CAPITAL PARTNERS GP, L.L.C. | LogicBio Therapeutics, Inc. | 1,165,448 | 5.0% | EDGAR |
SC 13G | 2019-02-12 | Barzel Adi | LogicBio Therapeutics, Inc. | 1,227,212 | 5.8% | EDGAR |